Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab

This study has been terminated.
(lack of enrollment)
Sponsor:
Collaborators:
Genentech, Inc.
Information provided by:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00287378
First received: February 3, 2006
Last updated: June 26, 2009
Last verified: February 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2007
  Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)